Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|SRC amp||lung non-small cell carcinoma||sensitive||Derazantinib||Case Reports/Case Series||Actionable||In a Phase I trial, Derazantinib (ARQ 087) treatment resulted in 25% tumor reduction and stable disease for 36 weeks in a squamous non-small cell lung carcinoma patient harboring SRC amplification (PMID: 28972963; NCT01752920).||28972963 detail...|
|PubMed Id||Reference Title||Details|
|Phase 1, first-in-human study of ARQ 087, an oral pan-Fibroblast Growth Factor Receptor (FGFR) inhibitor, in patients (pts) with advanced solid tumors.||Full reference...|
|(28972963)||A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours.||Full reference...|